Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 3-Year EBITDA Growth Rate is 72.30% as of Jun. 2026, which is 48% above its 10-year median of 49.00. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 804 Drug Manufacturers companies, PRF Technologies ranks better than 94.28% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 72.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 60.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of PRF Technologies was 72.30% per year. The lowest was -107.50% per year. And the median was 49.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PRF Technologies 3-Year EBITDA Growth Rate Related Terms
PRFX vs CTTH, UPC, AKAN: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PRF Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 72.30% mean?
PRF Technologies (PRFX) has a 3-Year EBITDA Growth Rate of 72.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PRF Technologies and its competitors. This is 48% above median its historical median of 49.00. According to the industry distribution chart, PRF Technologies ranks #46 out of 804 companies in the Drug Manufacturers industry, placing it in the top 5.7%.
Is PRF Technologies' 3-Year EBITDA Growth Rate too high?
PRF Technologies' current 3-Year EBITDA Growth Rate of 72.30% is 48% above median its 10-year median of 49.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. PRF Technologies' value of 72.30% is 712.4% above this industry median. Based on the distribution chart, PRF Technologies ranks #46 out of 804 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' 3-Year EBITDA Growth Rate compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #46 out of 804 companies for 3-Year EBITDA Growth Rate. This places PRF Technologies in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. PRF Technologies' value of 72.30% is 712.4% above this benchmark. While the company's 10-year median is 49.00 vs. the industry median of 8.90, PRF Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current 3-Year EBITDA Growth Rate of 72.30% is 712.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PRF Technologies and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current 3-Year EBITDA Growth Rate is 72.30%, which is 48% above median its own 10-year median of 49.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current 3-Year EBITDA Growth Rate of 72.30%. The current 3-Year EBITDA Growth Rate is 72.30%, which is 48% above median its 10-year median of 49.00 and 712.4% above the Drug Manufacturers industry median of 8.90. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PRF Technologies (PRFX), the current 3-Year EBITDA Growth Rate is 72.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
